Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives $4.50 Average Price Target from Analysts

Heron Therapeutics, Inc. (NASDAQ:HRTX) has been assigned a consensus recommendation of “Hold” from the five ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $4.50.

Several research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Heron Therapeutics in a research note on Friday, January 9th. Zacks Research raised Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 7th. Jefferies Financial Group reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, November 4th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Wednesday, October 8th.

Institutional Investors Weigh In On Heron Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. increased its stake in Heron Therapeutics by 57.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,028,678 shares of the biotechnology company’s stock worth $2,263,000 after acquiring an additional 373,518 shares during the last quarter. Congress Park Capital LLC lifted its position in shares of Heron Therapeutics by 11.4% during the second quarter. Congress Park Capital LLC now owns 2,268,249 shares of the biotechnology company’s stock worth $4,695,000 after purchasing an additional 232,632 shares during the last quarter. Palumbo Wealth Management LLC boosted its position in Heron Therapeutics by 6.7% in the 2nd quarter. Palumbo Wealth Management LLC now owns 132,433 shares of the biotechnology company’s stock valued at $274,000 after buying an additional 8,330 shares during the period. Cyndeo Wealth Partners LLC purchased a new stake in shares of Heron Therapeutics in the second quarter valued at approximately $514,000. Finally, AIGH Capital Management LLC lifted its holdings in shares of Heron Therapeutics by 8.3% in the 2nd quarter. AIGH Capital Management LLC now owns 3,009,257 shares of the biotechnology company’s stock worth $6,229,000 after buying an additional 231,057 shares during the period. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Trading Down 4.7%

Shares of NASDAQ:HRTX opened at $1.42 on Friday. The stock has a market capitalization of $260.37 million, a price-to-earnings ratio of -15.78 and a beta of 1.28. The company has a debt-to-equity ratio of 19.89, a quick ratio of 1.78 and a current ratio of 2.56. The stock’s 50-day simple moving average is $1.27 and its two-hundred day simple moving average is $1.39. Heron Therapeutics has a 52-week low of $1.00 and a 52-week high of $2.68.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.03). The firm had revenue of $38.21 million for the quarter, compared to analysts’ expectations of $39.03 million. Analysts expect that Heron Therapeutics will post -0.13 EPS for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.